Results 191 to 200 of about 139,940 (327)

Reorganization of Mitochondrial Function and Architecture in Response to Plant‐Derived Alkaloids: Anatabine, Anabasine, and Nicotine, Investigated in SH‐SY5Y Cells and in a Cellular Model of Parkinson's Disease

open access: yesCNS Neuroscience &Therapeutics, Volume 31, Issue 9, September 2025.
The effects of tobacco alkaloids: anatabine, anabasine, and nicotine, were investigated in a model of mitochondrial stress, mimicking cellular pathology accompanying Parkinson's disease development. The alkaloids modulated mitochondrial function and alleviated the hallmarks of mitochondrial stress. However, they acted via slightly different mechanisms.
Dominika Malińska   +11 more
wiley   +1 more source

Advances in Neurodegenerative Disease Therapy: Stem Cell Clinical Trials and Promise of Engineered Exosomes

open access: yesCNS Neuroscience &Therapeutics, Volume 31, Issue 9, September 2025.
This review provides a systematic evaluation of stem cell clinical trials (n = 94) to treat neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease. It also explores the emerging fields of preclinical and clinical investigations of stem cell‐derived exosome‐based therapies ...
Sevim Isik   +4 more
wiley   +1 more source

The Microbiota‐Gut‐Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders

open access: yesCNS Neuroscience &Therapeutics, Volume 31, Issue 9, September 2025.
The microbiota‐gut‐brain axis (MGBA) is a crucial regulator of neurological and neuropsychiatric disorders, with gut microbiota dysbiosis linked to various diseases. Gut microbiota changes can lead to neurodegenerative diseases like depression, autism, schizophrenia, Parkinson's, Alzheimer's, dementia, multiple sclerosis, epilepsy, anxiety, and autism ...
Md. Faysal   +12 more
wiley   +1 more source

Neuroimmune pathophysiology of long COVID

open access: yesPsychiatry and Clinical Neurosciences, Volume 79, Issue 9, Page 514-530, September 2025.
Although COVID‐19 was originally considered a respiratory illness, it is now well established that SARS‐CoV‐2 infection can have far‐reaching impacts on the nervous system. Neurological symptoms such as chemosensory dysfunction are frequently observed during acute infection and approximately 10% of COVID‐19 cases will go on to develop new or persistent
Janna K. Moen   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy